A late-stage study showed that at 48 weeks of treatment, ViiV Healthcare and Janssen's monthly, injectable two-drug regimen had similar efficacy to a once-daily, oral three-drug regimen in patients with HIV. The regimen's overall safety, virologic response and drug resistance results were consistent with earlier trial results.
Cellect Biotherapeutics and South Korean biotech Cell2in will collaborate on improving stem cell quality used for stem cell therapies. Cell2in's technologies will be tested by Cellect to provide more efficient quantification of mesenchymal stem cells and hematopoietic stem cells using ApoGraft technology versus current industry standards.
The Council of Scientific & Industrial Research's Institute of Microbial Technology in India and Epygen Biotech agreed to work together to develop the former's thrombolytic protein for the treatment of ischemic strokes. Under the deal's terms, CSIR-IMTECH transferred the technology to Epygen Biotech, which will take charge of preclinical studies and subsequent clinical trials.
Peasant farmers in Ghana wanted to adopt biotech seeds and animal breeds to meet the second goal in the country's Sustainable Development Goals, which is to have sustainable solutions to end hunger by 2030 and achieve food security. An agricultural biotechnology forum educated farmers about biotech foods, which farmers say guarantee food crop genetic diversity and increase production levels.
Researchers from Iowa State University evaluated data from an ethanol refinery in China's Shandong province and found that corncobs could be used as feedstock for ethanol production, according to a study published in Biofuels, Bioproducts and Biorefining. "Ethanol produced from corncob emits about 50% less greenhouse gas than from corn [grain]," said lead study author Wang Yu.
A round of Series C financing has brought in $45 million for South San Francisco, Calif.-based Profusa, a developer of tissue-integrating biosensors for continuous body chemistry monitoring. The proceeds will be used for commercialization of the Profusa Lumee Oxygen Platform and development of the company's glucose biosensor technology.
Capillary Biomedical has closed a round of seed financing led by Cove Fund, generating $2.9 million in proceeds. The company intends to use the money for regulatory filings, as well as to support the release of its SteadiSet insulin infusion technology in 2019.
OrthoPediatrics is poised to start a $1 million expansion of its Warsaw, Ind., headquarters. The project is expected to double the size of the space, adding room for offices and training and education facilities.
An underwritten public offering of common stock has been proposed by ViewRay in hopes of raising $125 million. Net proceeds from the offering, which will also include a 30-day option for the underwriters to buy $18.75 million worth of additional shares, will be used as working capital and for general corporate purposes.
Johnson & Johnson's Janssen Research & Development and HHS' Biomedical Advanced Research and Development Authority, along with J&J's JLABS incubators, have initiated a crowdsourced technology development challenge that aims to advance innovative respiratory protection devices. Winners of the QuickFire Challenge will be awarded up to $100,000.